Publicaciones


    Guías:

    1. Parsons JK, Dahm P, Köhler TS et al: Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline amendment 2020. J Urol 2020; 204: 799. Ver guía | Ver enmienda de 2020

    2. European Association of Urology (EAU) guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Ver guía

    3. Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association. Prog Urol 2021; 31(5): 249-265. Ver resumen

    4. NICE Medical Technologies Guidance (MTG58). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia 2021.
      View Guidance

    5. NICE Interventional Procedure Guidance (IPG475). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2014. View Guidance


    Metaanálisis:

    1. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. Int Urol Nephrol. 2020; 52(6): 999-1008. Ver resumen

    2. Jing J, Wu Y, Du M, et al. Urethral Lift as a Safe and Effective Procedure for Prostatic Hyplasia Population: A Systematic Review and Meta-Analysis. Front Surg. 2020; 8(7): 598728. Ver artículo

    3. Perera M, Roberts MJ, Suhail ARD, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015; 67; 704-713. Addendum Eur Urol 2015; 68; E53-E54. Ver resumen

    Estudios controlados y aleatorizados:

    1. L.I.F.T. Study
       
      1. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017; 24(3): 8802-8813. Ver artículo

      2. Roehrborn CG. Prostatic Urethral Lift A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urol Clin N Am. 2016. 43:357-369. Ver resumen

      3. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015; 22(3): 7772-82.
        Ver artículo

      4. Roehrborn CG, Gange SN, Shore ND, et al. Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study. Urology Practice. 2015; 2(1):26-32. Ver artículo

      5. McVary KT, Gange SN, Shore ND. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med. 2014; 11(1):279-87. Ver resumen

      6. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013; 190(6):2161-7. Ver resumen 

    2. BPH6 Study
       
      1. Gratzke C, Barber N, Speakman MJ. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017; 119(5):767-775. Ver artículo

      2. Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015; 68(4):643-52. Ver/descargar artículo 

    Estudios comparativos y no aleatorizados:

    1. Roehrborn CG, Rukstalis DB. Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. Eur Urol Focus. 2021; S2405-4569(20) 30315-1. Ver artículo

    2. Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol. 2020; 27(3): 10213-10219. Ver artículo 

    Estudios de un solo grupo:

    1. MedLift Study
       
      1. Rukstalis D, Grier D, Stroup SP, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 2019; 22(3): 411-419. Ver artículo
    2. Crossover Study
       
      1. Rukstalis D, Rashid P, Bogache W, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int. 2016; 118(Suppl 3): 14-22. Ver artículo

      2. Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014; 113(4):615-22. Ver resumen 
    3. LOCAL Study
       
      1. Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol. 2014; 21(1): 7094-101.* Ver artículo
    4. First-in-Human Study
       
      1. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: Two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012; 79(1): 5-11.* Ver resumen

      2. Woo HH, Bolton DM, Laborde E. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012; 9(2):568-75. Ver resumen

      3. Woo HH, Chin PT, McNicholas TA. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2011; 108(1): 82-8. Ver resumen
    5. Turkey Initial Study
       
      1. Bozkurt A, Karabakan M, Keskin E, Hirik E, Can Balci MB, Nuhoglu B. Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Urol Int. 2016; 96(2): 202-206. Ver resumen

      2. Akin Y, Bozkurt A, Keles MO, Gulmez H, Sahin M, Nuhoglu B. A Novel Minimally Invasive Treatment Option for Benign Prostat Hyperplasia: Intraprostatic UroLift®, The First Case Series of Turkey with Short Term Follow-up. JAREM. 2013; 3: 74-8. Ver artículo
    6. France Initial Study
       
      1. Beurrier S, Peyromaure M, Belas O, Delongchamps NB. Are the UroLift® implants an alternative for the treatment of benign prostatic hyperplasia? Short-term results and predictive factors of failure. Prog Urol. 2015; 25: 523-529. Ver resumen

      2. Delongchamps NB, Conquy S, Zerbib M, Peyromaure M. Intra-prostatic UroLift(®) implants for benign prostatic hyperplasia: preliminary results of the four first cases performed in France. Prog Urol. 2012; 22(10): 590-7. Ver resumen
    7. Spain Initial Study
       
      1. Garrido Abad P, Coloma Del Peso A, Sinues Ojas B, Fernandez Arjona M. Urolift®, a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results. Arch Esp Urol. 2013; 6696): 584-91. Ver resumen
    8. Large, Retrospective Real-World Studies
       
      1. Rabinowitz MJ, Alam R, Liu JL, et al. Prostatic Urethral Lift in Patients With Obstructive Median Lobes: A Single Surgeon Experience at an Academic Center. Urology. 2021; S0090-4295(21): 00088. Ver resumen

      2. Eure G, Gange S, Walter P, et al. Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. J Endourol. 2019; 33(7): 576-584. Ver artículo

      3. Sievert KD, Schonthaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol. 2019; 37(7):1353-1360. Ver artículo
    9. Chialastri P, Chialastri A, Mueller T. Does Prostatic Urethral Lift Reduce Urinary Medications? Trends in Medical Treatment Before and After Prostatic Urethral Lift. J Endourol. 2021; Jan 20. Ver resumen

    10. Kim JH, Lee KS, Kim TH et al. Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. World J Mens Health. 2020; 38(3):338-344. Ver artículo

    11. Userovici M, Ochoa A, Anract J, Beurrier S, Peyromaure M, Delongchamps NB. Prostatic urethral lift using Urolift® system for benign prostatic hyperplasia: 7 years experience. Prog Urol. 2020; 30(3): 147-154. Ver artículo

    12. Al-Singary W, Patel R, Obi-Njoku O, Patel HRH. The UroLift ® System for lower urinary tract obstruction: patient selection for optimum clinical outcome. Minim Invasive Ther Allied Technol. 2020; 11: 1-6. Ver resumen

    13. Cayuelas Rubio C, Pallas Costa Y, Juan Escudero J, et al. Minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. Our initial experience with Urolift® under local anaesthesia and sedation. Actas Urol Esp. 2019; 43(9): 488-494. Ver resumen

    14. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P. Prostatic Urethral Lift: Does Size Matter? J Endourol. 2018; 32(7): 635-638. Ver resumen

    15. Bardoli AD, Taylor WSJ, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. Aging Male. 2017; 20(3):192-197. Ver artículo 

    Artículos técnicos:

    1. Walsh LP. State of the art: Advanced techniques for prostatic urethral lift for the relief of prostate obstruction under local anesthesia. Can J Urol. 2017; 24(3):8859-8864. Ver artículo 

    2. McNicholas TA, Woo HH, Chin PT. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol. 2013; 64(2): 292-9. Ver resumen 

    3. Barkin J, Giddens J, Incze P. UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol. 2012; 19(2):6217-22.
      Ver artículo 

    Artículos de economía de la salud:

    1. Clarke JL. Optimizing Population Health and Economic Outcomes: Innovative Treatment for BPH. Popul Health Manag. 2013; 16(Suppl 2): S1-S13. Ver artículo 

    Información original

    *Indica que en el estudio se incluyeron volúmenes prostáticos superiores a los especificados en las indicaciones autorizadas por la FDA. El sistema UroLift no se debe utilizar si el volumen prostático del paciente es >100 ml.

    Teleflex no recomienda ni respalda el uso del sistema UroLift con volúmenes prostáticos >100 ml.

    Indicado para el tratamiento de los síntomas de agrandamiento de la próstata de hasta 100 cc en hombres de 45 años o más. Al igual que con cualquier procedimiento médico, los resultados individuales pueden variar. Los efectos secundarios más comunes son temporales e incluyen hematuria, disuria, urgencia miccional, dolor pélvico e incontinencia de urgencia (Roehrborn, J Urology 2013). Los efectos secundarios poco frecuentes, como el sangrado y la infección, pueden tener consecuencias graves y requerir intervención. Consulte las instrucciones de uso (IFU) para obtener más información.

    Contraindicado en hombres con hematuria macroscópica actual, infección del tracto urinario, incontinencia urinaria, afecciones uretrales que impidan la inserción del dispositivo o un volumen prostático superior a 100 cc.

    Teleflex, el logotipo de Teleflex, UroLift, el logotipo de UroLift, BPH Advisor, MyBPH Report y UroLift ATC son marcas comerciales o marcas registradas de Teleflex Incorporated o sus filiales en Estados Unidos y/u otros países.

    Calle Quito s/n – nave 1-5
    Polígono Industrial de Camporroso
    28806 Alcalá de Henares (Madrid)

    © 2025 Teleflex Inc. Reservados todos los derechos.    |    Condiciones de uso   |    Política de privacidad   |   Seguridad del paciente  |    Imprimir  |    Compliance
    MAC01373-07 Rev A